Section Review: Central & Peripheral Nervous Systems: Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease

References

• DAVIS K, YAMAMURA H: Cholinergic underactivity in human memory disorders. Life Sci. (1978) 23:1729–1734.
   PubMed Web of Science ®Google Scholar
• BARTUS RT, DEAN RU, BEER B, LIPPA AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217:408–417.
   PubMed Web of Science ®Google Scholar
• COYLE JT, PRICE DL, DELONG MR: Alzheimer's disease:a disorder of cholinergic innervation. Science (1983) 219:1184–1190,
   PubMed Web of Science ®Google Scholar
• CACABELOS R, NORDBERG AJC, FRANCO-MASIDE A, FER-NANDEZ-NOVOA L, GOMEZ MJ, ALVAREZ XA, TAKEDA M, PROUS J, JR, NISHIMURA T, WINBLAD B: Molecular strate-gies for the first generations of antidementia drugs (I). Tacrine and related compounds. Drugs of Today (1994) 30:295–337.
   Google Scholar
• MCBRIDE PE: The health consequences of smoking. Medical Clinics of North America (1992) 76:333–353.
   PubMed Web of Science ®Google Scholar
• CORRIGAL W: Nicotine addiction: considerations in the therapeutic use of nicotine. Med. Chem. Res, (1993) 2:603–611.
   Google Scholar
• OATES JA, WOOD AJJ, BENOWITZ NL: Pharmacologicaspects of cigarette smoking and nicotine addiction. New Engl. J. Med. (1988) 319:1318–1330.
   PubMed Web of Science ®Google Scholar
• BENOWITZ N: Nicotine and cardiovascular disease. In:Effects of Nicotine on Biological Systems: Advances in Phar-macological Sciences. Adlkofer F, Thurau K (Eds). Birkhauser Verlag, Basel (1991):579–596.
   Google Scholar
• BENOWITZ NL: Nicotine and coronary heart disease.Trends Cardiovasc. Med. (1992) 1:315–321.
   Web of Science ®Google Scholar
• KHOSLA S, LADDU A, EHRENPREIS S, SOMBERG JC: Car-diovascular effects of nicotine: relation to deleterious effects of cigarette smoking. Am. Heart]. (1994) 127:1669–16701
   PubMed Web of Science ®Google Scholar
• ARNERIC SP, SULLIVAN JP, WILLIAMS M: Neuronal nico-tinic acetykholine receptors: Novel targets for CNS therapeutics. In: Psychopharmacology.. Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds). Raven Press, New York (1995):94–110. A review of the pharmacology and therapeutic opportunity of ChCMs to treat a variety of CNS disorders.
   Google Scholar
• BANNON AW, DECKER MW, WILLIAMS M, ARNERIC SP: Psychotherapeutic potential of selective neuronal ace-tylcholine receptor ligands. In: Brain Imaging of Nicotine and Tobacco Smoking. Domino EF (Ed). NPP Books, Ann Arbor, MI (1995):311–334.
   Google Scholar
• ARNERIC SP, WILLIAMS M: Nicotinic agonists in Alzhe-imer's disease: does the molecular diversity of nicotine receptors offer the opportunity for developing CNS-se-lective cholinergic channel activators? Int. Acad. Biomed. Drug Res. Racagni G, Brunello N, Langer SZ (Eds). Karger, Basel (1994):58–70.
   Google Scholar
• ARNERIC SP, SULLIVAN JP, DECKER MW, BRIONI JD, BAN-NON AW, BRIGGS CA, DONNELLY-ROBERTS D, MARSH KC, KYNCL J, WILLIAMS M: Potential treatment of Alzhe-hner's disease using cholinergic channel activators (ChCAs) with cognition enhancement, aredolytic-like and cytoprotective properties. Alzheimer's Diseases & Associated Disorders (1995) 9:50–61.
   PubMed Web of Science ®Google Scholar
• ARNERIC SP, ANDERSON DJ, BANNON AW, BRIGGS CA, BUCCAFUSCO JJ, BRIONI JD, CANNON JG, DECKER MW, DONNELLY-ROBERTS D, GOPALAKRISHNAN M, HOL-LADAY MW, KYNCL J, MARSH KC, PAULY J, RADEK R, RODRIGUES AD, SULLIVAN JP: Preclinical pharmacology of ABT-418: a prototypical cholinergic channel activa-tor for the potential treatment of Alzhehner's disease. CNS Drug Rev. (1995) 1:1-26. A complete review of the pharmacology of ABT-418. Perhaps the first ChCM to be evaluated for the potential to treat AD.
   Google Scholar
• LEVIN ED: Nicotinic involvement in cognitive function: possible therapeutic applications. Med. Chem. Res. (1993) 2:612–627.
   Google Scholar
• WHITEHOUSE PJ: Cholinergic therapy in dementia. Acta Neurol. Scand. (1993) SuppL 149:42–45.
   Google Scholar
• CHANGEUX JP, GALZI JL, DEVILLERS-THIERY A, BETRAND D: The functional architecture of the acetylcholine nicotinic receptor explored by affinity labeling and site-directed mutagenesis. Quart. Rev. Biophys. (1992) 25:395–432.
   PubMed Web of Science ®Google Scholar
• LENA C, CHANGEAUX J-P: Allosteric modulations of thenicotinic acetykholine receptor. Trends Neurosci. (1993) 16:181–186.
   PubMed Web of Science ®Google Scholar
• SARGENT PB: The diversity of neuronal nicotinic acetyl- choline receptors. Ann. Rev. Neurosci. (1993) 16:403-43. A detailed review of the neurobiology related to nAChRs.
   Google Scholar
• MCGEHEE DS, ROLE LW: Physiological diversity of nico-tinic acetyldmline receptors expressed by vertebrate neurons. Ann. Rev. Physiol. (1995) 57:521-546. An excellent review of the recent neurobiological findings related to nAChRs.
   Google Scholar
• SIEGHART W: Ligand-gated Ct ion channels modulatedby multiple drug-binding sites. Trends Pharmacol. Sci. (1992) 13:446–450.
   PubMed Web of Science ®Google Scholar
• KEMP JA, LEESON PD: The glycine site of the NMDAreceptor - five years on. Trends Pharmacol. Sci. (1993) 14:20–25.
   PubMed Web of Science ®Google Scholar
• ORTELLS MO, LUNT GC: Evolutionary history of the ligand-gated ion-channel superfamily of receptors. Trends Neurosci. (1995)18:121–127.
   PubMed Web of Science ®Google Scholar
• BERTAND D, CHANGEUX JP: Nicotinic receptor: an allos- •teric protein specialized for intercellular communica- tion. The Neurosciences (1995) 7:75-90. An excellent synopsis of the allosteric nature of neuronal nAChRs and ligands that may modulate the function of these proteins.
   Google Scholar
• ELGOYHEN AG, JOHNSON DS, BOULTER J, VE 1 IER DE, IIEINEMANN S: a9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell (1994) 79:705–715.
   PubMed Web of Science ®Google Scholar
• ANAND R, LINDSTROM J: Nucleotide sequence of thehuman nicotinic acetylcholine receptor 132 subunit gene. Nucleic Acids Res. (1990) 18:4272–4278.
   PubMed Web of Science ®Google Scholar
• CIIINI B, CLEMENTI F, HUKOVIC N, SHER E: Neuronal a-bungarotoxin receptors and the a3-nicotinic recep-tor subunit gene are expressed in neuronal and non-neuronal human cell lines. Proc. Natl. Acad. Sci. USA (1992) 89:1572-1576.44.
   Google Scholar
• DOUCETTE-STAMM L, MONTEGGIA L, DONNELLY-ROBERTS D, WANG WT, TIAN JL, GIORDANO T: Cloning and sequence of the human a7 nicotinic acetylcholine receptor. Drug Dev. Res. (1994) 30:252–256.
   Web of Science ®Google Scholar
• TARRONI P, RUBBOLI F, CHINI B: Neuronal-type nico-tinic receptors in human neuroblastoma and small-cell lung carcinoma cell lines. FEBS Lett. (1992) 312:66–70.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RD, MCGEE R, KELLAR KJ: Nicotinic cholin-ergic receptors labeled by PM-acetylcholine in rat brain. Mol. Pharm. (1982) 22:55–62.
   Google Scholar
• MARKS MJ, STITZEL JA, ROMM E, WEHNER JM, COLLINSAC: Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and a-bungaro-toxin. Mol. Pharrnacol. (1986) 30:427–436.
   PubMed Web of Science ®Google Scholar
• PABREZA LA, DHAWAN S, KELLAR KJ: PM-Cytisine bind-ing to nicotinic cholinergic receptors in brain. Mol. Pharmacol. (1991) 39:9–12.
   PubMed Web of Science ®Google Scholar
• CLARICE PBS, PERT A: Autoradiographic evidence fornicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. (1985) 348:355–358.
   PubMed Web of Science ®Google Scholar
• SCHULZ DW, LORING RH, AIZENMANN E, ZIGMOND RE:Autoradiographic loc•lization of putative nicotinic re-ceptors in the rat brain using [1251]-neuronal bungaro-toxin. J. Neurosci. (1991) 11:287–297.
   PubMedGoogle Scholar
• FLORES CM, ROGERS SW, PABREZA IA, WOLFE BB, KEL-LAR KJ: A subtype of nicotinic cholinergic receptor in rat brain is composed of a4 and 02 subunits and is up-regulated by chronic nicotine treatment Mol. Phar-macol. (1991) 41:31–37.
   Web of Science ®Google Scholar
• SEGUELA P, WADICHE J, DINELEY-MILLER K, DANI JA,PATRICK JW: Molecular cloning, functional properties, and distribution of rat brain a7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. (1993) 13:596–604.
   PubMed Web of Science ®Google Scholar
• COURT J, CLEMENT' F: Distribution of nicotinic subtypesIn human brain. Alz. Dis. Assoc. Disorders (1995) 9:6–14.
   PubMed Web of Science ®Google Scholar
• DECKER MW, BRIONI JD, BANNON AW, ARNERIC SP: Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS thera-peutics. Life Sci. (1995) 56:545–570.
   PubMed Web of Science ®Google Scholar
• WI IITING P, SCHOEPFER R, LINDSTROM J, PRIESTLEY T:Structural and pharmacologic characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol. Pharmacol. (1991) 40:463–472.
   PubMed Web of Science ®Google Scholar
• PUCHACZ E, BUISSON B, BERTRAND D, LUKAS R: Func-tional expression of nicotinic acetykholine receptors containing rat a7 in human SH-SY5Y neuroblastoma cells. FEBS Lett. (1994) 354:155–159.
   PubMed Web of Science ®Google Scholar
• WONG ET, IIOLSTAD SG, MENNERICK SI, HONG SE, ZORUMSKI CF, ISENBERG KE: Pharmacological and physiological properties of a putative ganglionic nico-tinic receptor, a304, expressed in trans fected eucaryotic cells. Mol. Brain Res. (1995) 28:101–109.
   PubMedGoogle Scholar
• GOPALAKRISIINAN M, BUISSON B, TOLIMA E, GIORDANOT, CAMPBELL JE, HU IC, DONNELLY-ROBERTS D, ARNERIC SP, BERTRAND D, SULLIVAN JP: Stable expression and pharmacological properties of the human a7 nicotinic acetylcholine receptor. Eur.J. Pharmacol. (1995) 290:237–246.
   PubMed Web of Science ®Google Scholar
• GOPALAKRISHNAN M, MONTEGGIA LM, ANDERSON DJ, ARNERIC SP, SULLIVAN JP: Stable expression, pharma-cologic properties and regulation of the human nico-tinic acetylcholine a4132 receptor. J. Pharmacol. Exp. Ther. (1995). In press.
   Google Scholar
• PAPKE RL: The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity. Prog. Neurobiol. (1993) 41:509–531.
   PubMed Web of Science ®Google Scholar
• PAPKE RL, HEINEMANN SF: Partial agonists properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit. Mol. Pharmacol. (1993) 45:142–149.
   Web of Science ®Google Scholar
• PAPKE RL, DUVOISIN RM, HEINEMANN SF: The amino terminal half of the nicotinic 0-subunit extracellular domain regulates the kinetics of inhibition by neuronal bungarotoxin. Proc. Royal Soc. Lond, B(1993) 252:141–148.
   PubMed Web of Science ®Google Scholar
• PEREIRA EFR,11EINHARDT-MAELICKE S, SCHRA'fTENHOLZ A, MAELICKE A, ALBUQUERQUE EX: Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippo-campal neurons. J. Pharmacol. Exp. Ther. (1993) 265:1474–1491.
   PubMed Web of Science ®Google Scholar
• MAELICKE A, SCHRATTENHOLZ A, SCHRODER H: Modu- latory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system. The Neurosciences (1995) 7:103-114. An excellent synopsis of the current status of what is known about non-competitive agonists of nAChRs.
   Google Scholar
• LUETJE CW, WADA K, ROGERS S, ABRAMSON SN, TSUJI K, HEINEMANN S, PATRICK J: Neurotoxins distinguish be-tween different neuronal nicotinic acetylcholine recep-tor subunit combinations. J. Neurochem. (1990) 55:632-640. One of the pioneering papers that convincingly demonstrates that subunit diversity of the neuronal nAChRs can be translated into substantial pharmacologic diversity.
   Google Scholar
• VIJAYARAGHAVAN S, PUGH, PC, ZANG, Z-W, RAFTERY, MM, BERG, DK: Nicotinic receptors that bind a-bungaro-toxin on neurons raise intracellular free calcium. Neu-ron (1992) 8:127–134.
   Google Scholar
• ALKONDON M, ALBUQUERQUE EX: Diversity of nicotinicacetylcholine receptors in rat hippocampal neurons. L Pharmacological and functional evidence for distinct structural subtypes. J. Pharmacol. Exp. Ther. (1993) 265:1455–1473.
   PubMed Web of Science ®Google Scholar
• ALBUQUERQUE EX, PEREIRA EFR, CASTRO NG, ALKON-DON M, REINHARDT S, SCHROEDER H, MAELICKE A: Nicotinic receptor function in the mammalian central nervous system. Ann. NY Acad. Sci. (1995) 757:48–72.
   PubMed Web of Science ®Google Scholar
• VERNINO S, AMADOR M, LUETJE CW, PATRICK J, DANI JA: Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron (1992) 8:127–134.
   PubMed Web of Science ®Google Scholar
• DAMAJ MI, WELCH SP, MARTIN BR: Involvement of cal-cium and L-type channels in nicotine-induced analge-sia. J. Pharmacol. Exp. Ther. (1993) 266:1330–1338.
   PubMed Web of Science ®Google Scholar
• DONNELLY-ROBERTS D, ARNERIC SP, SULLIVAN JP: Func-tional modulation of human `ganglionic-like' neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists. Biochem. Biophys. Res. Comm. (1995) 213:657–662.
   PubMed Web of Science ®Google Scholar
• MARKS MJ, FARNHAM DA, GRADY SR, COLLINS AC: Nico-tinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. (1993) 264:542–552.
   PubMed Web of Science ®Google Scholar
• WILKIE GI, HUTSON PH, STEPHENS MW, WHITING P, WONNACOTT S. Hippocampal nicotinic autoreceptors modulate acetykholine release. Biochem. Soc. Trans. (1993) 21:429–431.
   PubMedGoogle Scholar
• LUKAS RJ: Expression of ganglia-type nicotinic acetyl-choline receptors and nicotinic binding sites by cells of the MR-32 human neuroblastoma clonal line. J. Phar-macol. Exp. Ther. (1993) 265:294–302.
   PubMed Web of Science ®Google Scholar
• GRADY S, MARKS MJ, WONNACOTT S, COLLINS AC: Char-acterization of nicotinic receptor-mediated [3111-dopamine release from synaptosomes prepared from mouse striatun“ Neurochem. (1992) 59:848-856.
   Google Scholar
• PERRY EK, TOMLINSON BE, BLESSED G, BERGMANN K, GIBSON PH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. J. Pharmacol. (1978) 2:1457–1459.
   Web of Science ®Google Scholar
• DASTLR DK: Cerebral blood flow and metabolism in normal human aging, pathological aging and senile dementia. J. Cerebral Blood Flow & Metab. (1985) 5:1–9.
   PubMed Web of Science ®Google Scholar
• RIEKKINEN P. BUZSAKI G, R1EKKINEN P JR, SOININEN H, PARTANEN J: The cholinergic system and EEG slow waves. Electroencephalogr. Clin. Neurophysiol. (1990) 78:89–96.
   Google Scholar
• NORDBERG A: Human nicotinic receptors-their role in aging and dementia. Neurochem. Int. (1992) 25:93–97.
   Web of Science ®Google Scholar
• GREENAMYRE JT, MARAGOS WF: Neurotransmitter re-ceptors in Alzheimer's disease. Cerebrovasc. Brain Metab. Rev. (1993) 5:61–94.
   PubMedGoogle Scholar
• SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL D, ST. GEORGE-IlYSLOP PH, PERICAK-VANCE MA, J00 SH, RODI BL, GUSELLA JF, CRAPPER-MACLACHLAN DR, ALBERTS MJ, HULETTE C, GRAIN B, GOLDGABER D, ROSES AD: Asso-ciation of apolipoprotein E allele 64 with late-onset familial and sporadic Alzheimer's disease. Neurology (1993) 43:1467–1472.
   PubMed Web of Science ®Google Scholar
• GRACON SI. KNAPP MJ: Tacrine: An overview of efficacy in two parallel group studies. In: Alzheimer's Disease. Therapeutic Strategies. Giacobini E, Becker R (Eds). Birk-hauser, Boston (1994):145–149.
   Google Scholar
• SCHWARZ RD, CALLAHAN MJ, DAVIS RE, JAEN JC, LIPENSKI W, BABY C, SPENCER CJ, TECLE H: Selective muscarinic agonists for Alzheimer disease treatment. In: Alzhe-imer's Disease: Therapeutic Strategies. Giacobini E, Becker R (Eds). Birkhauser, Boston (1994):224–228.
   Google Scholar
• SHANNON HE, BYMASTER FP, CALLIGARO DO, GREEN-WOOD B. MITCI I CH, WARD JS, SAUERBERG P, OLESEN P, SI IFARDOWN M, SWEDBERG MBD, SUZDAK PD: Xanome-line: An efficacious and specific MI receptor agonist - preclinical update. In: Alzheimer's Disease: Therapeutic Strategies. Giacobini E, Becker R (Eds). Birkhauser, Boston (1994):229–233.
   Google Scholar
• I3ODICK NC, DELONG AF. BONATE PL, GILLESPIE T, HENRY DP, SA IIhRWHITE pi, LUCAS RA, HEATON J,CARTER GV, FARDE L, CUTLER NR, SRAMEK JJ, SEIFERT RD, CONRAD JJ, WARDLE TS: Xanomeline, a specific Mi. agonist: Early clinical studies. In: Alzheimer's Disease: Therapeutic Strategies. Giacohini E, Becker R (Eds). Birk-hauser, Boston (1994):234–238.
   Google Scholar
• ZACZEK R. CHORVAT RJ, EARL RA, TAM SW: Neurotrans-mitter release enhancement as a possible therapy for neurodegenerative disease: Update on linopirdine (DuP 996). In: Alzheimer's Disease. Therapeutic Strategies. Giacobini E, Becker R (Eds). Birkhauser, Boston (1994):252–255.
   Google Scholar
• NITSCH RM, GROWDON JH, FARBER SA, DENG M, WURT-MAN RJ: Regulation of APP processing by first messen-gers. In: Alzheimer's Disease: Therapeutic Strategies. Giacobini E, Becker R (Eds). Birkhauser, Boston (1994)54–61.
   Google Scholar
• HU J, WANG S-Z, EL-FAKAHANY EE: Effects of agonist efficacy on desensitization of phosphoinositide hy-drolysis mediated ml and m3 muscarinic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. (1991) 257:938–945.
   PubMed Web of Science ®Google Scholar
• WHITEHOUSE PJ: Neurotransmitter receptor alterations in Alzheimer disease: A Review. Alzheimer Disease and Associated Disorders (1987) 1:9–18.
   PubMedGoogle Scholar
• WHITEHOUSE PJ: Parkinson's disease and Alzheimer'sdisease: New neurochemical parallels. Movement Disor-ders (1989) 4:857-862. SMITH CJ, GIACOBINI E: Nicotine, Parkinson's and Alzheimer's Disease. Rev. Neurosci. (1992) 3:25-43. COURT JA, PERRY ER: CNS nicotinic receptors. Possible therapeutic targets in neurodegenerative disorders. CNS Drugs (1994) 2:216–233.
   Google Scholar
• SCHRODER H, GIACOBINI E, WEVERS A, BIRTSCH C, SCHUTZ U: Nicotinic receptors in Alzheimer's disease. In: Brain Imaging of Nicotine and Tobacco Smoking. Dom-ino EF (Ed). NPP Books, Ann Arbor, MI (1995):311–334.
   Google Scholar
• VAN DUIJN CM, HOFMAN A: Relation between nicotineIntake and Alzheimer's disease. Br. J. Med. (1991) 302:1491–1494.
   PubMed Web of Science ®Google Scholar
• POIRIER J, AUBERT I, BERTRAND P, QUIRION R, GAUTH-IER S, NALBANTOGLU J: Apolipoprotein E4 and cholin-ergic dysfunction in AD. In: Alzheimer's Disease: Therapeutic Strategies. Giacobini E, Becker R (Eds). Birk-hauser, Boston (1994):72–76.
   Google Scholar
• LEVIN ED: Nicotinic systems and cognitive function. Psychopharmacology (1992) 108:417–431.
   PubMed Web of Science ®Google Scholar
• DECKER MW, MAJCIWZAK MJ, ANDERSON DJ: Effects of nicotine on spatial memory deficits in rats with medial septal lesions. Brain Res. (1992) 572:281–285.
   PubMed Web of Science ®Google Scholar
• WIDZOWSKI DV, CREGAN E, BIALOBOK P: Effects of nicotinic agonists and antagonists on spatial working memory in normal adult and aged rats. Drug Dev. Res. (1994) 31:24–31.
   Web of Science ®Google Scholar
• BUCCAFUSCO JJ, JACKSON WJ: Beneficial effects of nico-tine administered prior to a delayed matching-to-sam-ple task in the young and aged monkeys. Neurobiol. Aging (1991) 12:233–238.
   PubMed Web of Science ®Google Scholar
• TURCHI J, HOLLEY LA, SARTER M: Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. Psychopharmacology (1995) 118:195–205.
   PubMed Web of Science ®Google Scholar
• WOODRUFF-PAK DS, LI Y-T, KAZMI A, REM WR: Nicotinic cholinergic system involvement in eyeblink classical conditioning in rabbits. Behar. Neurosci. (1994) 108:486–493.
   PubMed Web of Science ®Google Scholar
• EVENDON JL, TURPIN M, OLIVER L, JENNINGS C: Caffeine and nicotine improve visual tracking by rats: a compari-son with amphetamine, cocaine and apomorphine. Psychopharmacology (1993) 110:169–17690. •
   Google Scholar
• WONNACOTT S, IRONS J, RAPIER C, THORNE B, LUNT GG:Presynaptic modulation of transmitter release by nico-tinic receptors. In: Progress in Brain Research Nordberg A, Fuxe K, Holmstedt B (Eds). Elsevier Science Publishers (1989):157–163.
   Google Scholar
• VIZI ES, SERSHEN H. BALLA A, MIKE A, WINDISCH,K,JURANYI ZS, LAJTHA A: Neurochemical evidence of het-erogeneity of presynaptic and somatodendritic nico-tinic acetylcholine receptors. Ann. IVY Acad. Sci. (1995) 757:84–99.
   PubMed Web of Science ®Google Scholar
• MCGEHEE DS, HEATH MJS, GELBER S, DEVAY P, ROLE LW: •Nicotine enhancement of fast excitatory synaptic trans-mission in CNS by presynaptic receptors. Science (1995) 269:1692-1696. An important paper that elegantly identifies what may be one of the most important functions of nAChR-mediated actions in the CNS.
   Google Scholar
• SAHAK1AN B, JONES G, LEVY R, GRAY J, WARBURTON D:The effects of nicotine on attention, information proc-essing, and short term memory in patients with demen-tia of the Alzheimer type. Br. J. Psychiatry (1989) 154:797–800.
   PubMed Web of Science ®Google Scholar
• SAHAKIAN BJ, COULL JT: Nicotine and tetrahydroami-noacridine: evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev. Res. (1994) 31:80–88.
   Web of Science ®Google Scholar
• NEWHOUSE PA, POTTER A, LENOX RH: The effects ofnicotinic agents on human cognition: possible thera-peutic applications in Alzheimer's and Parkinson's dis-eases. Med. Chem. Res. (1993) 2:628–642.
   Google Scholar
• KATAYAMA S, HIRATA K, TANAKA H, YAMAZAKI K, FUJI-KANE M, ICHIMARU Y: Efficacy of transdermal nicotine in dementia: a study using event-related potentials and middle latency response. In: Brain Imaging of Nicotine and Tobacco Smoking. Domino EF (Ed). NPP Books, PO Box 1491, Ann Arbor, MI 48106 (1995):289–302.
   Google Scholar
• WILSON AL, LANGLEY LK, MONLEY J, BAUER T, ROT-TUNDA S, MCFALLS E, KOVERA C, MCCARTEN JR: Nicotine patches in Alzheimer's Disease: Pilot study on learning, memory, and safety. Pharmacol. Biochem. Bebav. (1995) 51:509–514.
   PubMed Web of Science ®Google Scholar
• PRESTON GC: 5-HT3 Antagonists and disorders of cog-nition. In: Recent Advances in the Treatment of Neurodegen-erative Disorders and Cognitive Dysfunction. Racagni G, Brunello N, Langer SZ (Eds). Int. Acad. Biomed. Drug Res. (1994) 7:89–93.
   Google Scholar
• LITTLE JT, BROOCKS A, MARTIN A, HILL JL, TUNE LE, MACK C, CANTILLON M, MOLCHAN S, MURPHY DL, SUNDER-LAND T: Modulation of anticholinergic effects on cog-nition and behavior in elderly humans. Psychopharrnacology (1995) 120:280–288.
   PubMed Web of Science ®Google Scholar
• POMERLEAU OF: Nicotine as a psychoactive drug: Anxi-ety and pain reduction. Psychopharrnacol. Bull. (1986) 22:865–869.
   PubMed Web of Science ®Google Scholar
• BRIONI JD, O'NEILL AB, KIM DJB, DECKER MW: Nicotinicreceptor agonists exhibit arutiolytic-like effects on the elevated plus-maze test. Eur.J. Pharmacol. (1993) 238:1–8.
   PubMed Web of Science ®Google Scholar
• COSTALL B, KELLY ME, NAYLOR RJ, ONAIVI ES: The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol. Biocbem. Behav. (1989) 33:197.
   PubMed Web of Science ®Google Scholar
• GILI3ERT DG. Paradoxical tranquilizing and emotion-re-ducing effect of nicotine. Psychol. Bull. (1979) 86:643–661.
   PubMed Web of Science ®Google Scholar
• GILBERT DG, ROBINSON JH, CHAMBERLIN CL, SPIELBER-GER CD: Effects of smoking nicotine on anxiety, heart rate and lateralization of EEG during a stressful movie. Psychophysiology (1989) 26:311–319.
   PubMed Web of Science ®Google Scholar
• VENDER JR, NAIR SN, LEHMAN JC: NMDA receptors: the first decade. Exp. Opin. Invest. Drugs (1994) 3:341–354.
   Google Scholar
• AKAME A, TAMURA Y, YOKOTA T, SHIMOHAMA S, KIMURA J: Nicotine-induced protection of cultured cor-tical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. (1994) 644:181–187.
   PubMed Web of Science ®Google Scholar
• MARIN P, MAUS M, DESAGHER S, GLOWINSKI J, PREMONT J: Nicotine protects cultured striatal neurones against N-Methyl-D-aspartate receptor-mediated neurotoxicity. Neuroreport (1994) 5:1977–1980.
   PubMed Web of Science ®Google Scholar
• DONNELLY-ROBERTS D, HU I, ARNERIC SP, SULLIVAN JP: In vitro cytoprotective properties of the novel cholin-ergic channel activator (ChCA), ABT-418. Brain Res (1995). In Press.
   Google Scholar
• OWMAN C, FUXE K, JASON AM, KAHRSTROM J: Studies of protective actions of nicotine on neuronal and vascular functions in rats: comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber system, and the effect of a dopamine agonist. Prog. Brain Res. (1989) 79:267–276.
   PubMed Web of Science ®Google Scholar
• RATHOUZ MM, BERG DK: Synaptic-type acetykholine receptors raise intracellular calcium levels in neurons by two mechanisms. J. Neurosci. (1994) 14:6935–6945.
   PubMed Web of Science ®Google Scholar
• FREEDMAN, R, WETMORE, C, STROMBERG, I, LEONARD, S, OLSON, L: a-Bungarotoxin binding to hippocampal neurons: immunocytochemical characterization and effects on growth factor expression. J. Neurosci. (1993) 13:1965–1975.
   PubMed Web of Science ®Google Scholar
• TREININ M, CHALFIE M: A mutated acetylcholine recep-tor subunit causes neuronal degeneration in C. elegans. Neuron (1995) 14:871–877.
   PubMed Web of Science ®Google Scholar
• GIACOBINI E: Cholinergic receptors in human brain: effects of aging and Alzheimer disease. J. Neurosci. Res. (1990) 27:548–560.
   PubMed Web of Science ®Google Scholar
• TERRY AV, Jr., CLARKE MSF: Nicotine stimulation of nerve growth factor receptor expression. Life Sci. (1994) 55:PL91-PL98.
   Google Scholar
• MARTIN J, PANICKAR KS, KING MA, DEYRUP M, HUNTER BE, WANG G, MEYER EM: Cytoprotective actions of 2,4-dimethoxybenzylidene anabaseine in differenti-ated PC12 cells and septal cholinergic neurons. Drug Dev. Res. (1994) 31:135–141.
   Web of Science ®Google Scholar
• JANSON AM, FUXE K, AGNATI LF, JASSON A, BJEKLKE B, SUNDSTROM E, ANDERSON K, HARFSTRAND A. GOLD-STEIN M, OWMAN C: Protective effects of chronic nico-tine treatment on lesioned nigrostriatal dopamine neurons in the male rat. Frog. Brain Res. (1989) 79:257–265.
   PubMed Web of Science ®Google Scholar
• JANSON AM, MOLLER A: Chronic nicotine treatment counteracts nigral cell loss induced by a partial meso-diencephalic hemitransection: An analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience (1993) 57:931–941.
   PubMed Web of Science ®Google Scholar
• WONNACOTT S: The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci. (1990) 11-216–219
   Google Scholar
• SOLDATOS CR, KALES JD, SCHARF MB, 131XLER,E0, KALES A: Cigarette smoking associated with sleep difficulty. Science (1980) 207: 551–553.
   PubMed Web of Science ®Google Scholar
• PICCIOTTO MR, ZOLL M, LENA C, BESSIS A, LALLEMAND Y, LENOVERE N, VINCENT P, PICH EM, SRC:LET P, CHANGEUX JP: Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature (1995) 374:65–67.
   PubMed Web of Science ®Google Scholar
• SHERIDAN RP, NILAKANTAN R, DIXON JS, VENKATARAGHAVAN R: The ensemble approach to dis-tance geometry: application to the nicotinic pharmaco-phore. J. Med. Chem. (1986) 29:899–906.
   PubMed Web of Science ®Google Scholar
• SPIVAK CE, GUND TM, LIANG RE: Structural and elec-tronic requirements for potent agonists at a nicotinic receptor. Eur. J. Phannacol. (1986) 120:127–131.
   PubMed Web of Science ®Google Scholar
• BARLOW RB, JOHNSON 0: Relations between structure and nicotine-like activity: X-ray crystal structure analy-sis of (-)-cytis• ine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds. Br. J. Pharmacol. (1989) 98:799–808.
   PubMed Web of Science ®Google Scholar
• DEVILLERS-THIERY A, GALZI JL, EISELE JL, BERTRAND S, BERTRAND D, CHANGEUX JP. Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels. J. Membrane Biol. (1993) 136:97–112.
   Google Scholar
• SINE SM, QUIRAM P, PAPANIKOLAOU F, KREIENKAMP H-J, TAYLOR P: Conserved tyrosines in the a subunit of the nicotinic acetylcholine receptor stabilize quaternary ammonium groups of agonists and curariform antago-nists. J. Biol. Chem. (1994) 269:8808–8816.
   PubMedGoogle Scholar
• AYLWIN ML, WHITE MM: Ligand-receptor interactions in the nicotinic acetykholine receptor probed using mul-tiple substitutions at conserved tyrosines on the a subunit. FEBS Lett. (1994) 349:99–103.
   PubMed Web of Science ®Google Scholar
• TOMASELLI GF, MCLAUGHLIN JT, JURMAN ME, HAWROT E. YELLEN G: Mutations affecting agonist sensitivity of the nicotinic acetykholine receptor. Biophys. J. (1991) 60:721–727.
   PubMed Web of Science ®Google Scholar
• CZAKOWSKI C, KAUFMANN C, KARLIN A: Negatively charged amino acid residues in the nicotinic receptor d subunit that contribute to the binding of acetyl-choline. Proc. Natl. Acad. Sci. USA (1993) 90:6285–6289.
   PubMed Web of Science ®Google Scholar
• CZAJKOWSKI C, KARLIN A: Structure of the nicotinic receptor acetylcholine-binding site. Identification of acidic residues in the 8 subunit within 0.9 tun of the a subunit-binding site disulfide. J. Biol. Chem. (1995) 270:3160–3164.
   Google Scholar
• IIAREL M, SCHALK I, EHRET-SABATIER L, BOUET F, GOELDNER M, I IIRTH C, AXELSEN PH, SELMAN I, SUSSMAN JL: Quaternary ligand binding to aromatic residues in the active-site gorge of acetykholinesterase. Proc. Natl. Acad. Sci. USA (1993) 90:9031–9035.
   PubMedGoogle Scholar
• SUSSMAN JL, IIAREL M, FROLOW F, OEFNER C, GOLDMAN A. TOKER L. SELMAN I: Atomic structure of acetylcholi-nes terase from Torpedo californica: a prototypic ace-tylcholine-binding protein. Science (1991) 253:872–879.
   Google Scholar
• TRIGGLE DW: Analogs and antagonists of acetylcholine and norepinephrine: the relationships between chemi-cal structure and biological activity. In: Neurotransmit-ter-Receptor Interactions. Academic Press, London (1971):209–399.
   Google Scholar
• WESS J, BUHL T, LAMBRECHT G, MUTSCHLER E: Cholin-ergic receptors. In: Comprehensive Medicinal Chemistry. Hansch C, Sammes PG, Taylor JB, Emmett JC (Eds). Per-gamon (1990):423.
   Google Scholar
• ANDERSON DJ, ARNERIC SP: Nicotinic receptor binding of [311]-cytisine, [3111-nicotine and [311]-methylcarbamyl-choline in rat brain. Eur.J.Pharmacol. (1994) 253:261–267.
   PubMed Web of Science ®Google Scholar
• HAPPE HK, PETERS JL, BERGMAN DA, MURRIN LC: Local-ization of nicotinic cholinergic receptors in rat brain: autoradiographic studies with [311]-cytisine. Neurosci-ence (1994) 62:929–944.
   PubMed Web of Science ®Google Scholar
• HOLLADAY MW, LEBOLD SA, LIN N-H: Structure-activity esrelationships of nicotinic acetylcholine receptoragonists as potential treatments for dementia. Drug Dev. Res. (1995) 35:191-213. A current review of the structure activity relationship of compounds that primarily interact with neuronal nAChRs.
   Google Scholar
• LIN N-H, CARRERA GM, Jr., ANDERSON DJ: Synthesis and evaluation of nicotine analogs as neuronal nicotinic acetylcholine receptor ligands, J. Med. Chem. (1994) 37:3542–3553.
   PubMed Web of Science ®Google Scholar
• LIN N-H, HE Y, ANDERSON DJ, WASICAK JT, KASSON R, SWEENY D, SULLIVAN JP: Synthesis and structure-activ-ity relationships of pyrrolidine-modified analogs of the potent cholinergic channel activator, ABT-418. Bioorg. Med. Chem. Lett. (1994) 4:2389–2394.
   Web of Science ®Google Scholar
• GLENNON RA, MAAROUF A, FAHMY S, MARTIN B, FAN F, YOUS1F M, SHAFIK RM, DUKAT M: Structure-affinity relationships of simple nicotine analogs. Med. Chem. Res. (1993) 2:546–551.
   Google Scholar
• KANNE DB, ABOOD LG: Synthesis and biological char-acterization of pyridohomotropanes. Structure-activity relationships of conformationally restricted nicoti-noids. J. Med. Chem. (1988) 31:506–509.
   Google Scholar
• GARVEY DS, WASICAK JT, DECKER MW, BRION' JD, BUCK-LEY MI, SULLIVAN JP, CARRERA GM, HOLLADAY MW, ARNER1C SP, WILLIAMS M: Novel isoxazoles which inter-act with brain cholinergic channel receptors have in-trinsic cognitive enhancing and anxiolytic activities. J. Med. Chem. (1994) 37:1055–1059.
   PubMed Web of Science ®Google Scholar
• GLENNON RS, FIEDLER W, DUKAT M, DAMAJ, I, MARTIN BR, DUMAS D, ROSECRANS JA, JAMES JR: Pyrrolidine-modified analogues of nicotine: a structure-affinity in-vestigation. J. Med. Chem. (1995). In press.
   Google Scholar
• CATKA TE, LEETE E: Synthesis of a 'bridged nicotine': 1,2,3,3,6,10b-hexahyrodpyrido[2,3-g1 indolizine. J. Org. Chem. (1978) 43:2125–2127.
   Web of Science ®Google Scholar
• CHAVADARIAN CG, SEEMAN JI, WOOTEN JB: Bridged nicotines. Synthesis of cis-2,3,3a,4,5,9b-hexahydro-1-methy1-1H-pyrrolo[2,3-fiquinoline. J. Org. Chem. (1983) 48:492–494.
   Google Scholar
• GLASSCO W, SUCIIOCKI J, GEORGE C, MARTIN BR, MAY EL: Synthesis, optical resolution, absolute configuration and preliminary pharmacology of (+) and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo[3,2-1/1i soquinoline, a structural analog of nicotine. J. Med. Chem. (1993) 36:3381–3385.
   PubMed Web of Science ®Google Scholar
• BENCHERIF M, LOVE ITE ME, ARRINGTON S, FOWLER K, REEVES L. CALDWELL WS, LIPPIELLO PM: Metanicotine: a nicotinic agonist with CNS selectivity-in vitro charac-terization. Neurosci. Abstr. (1995) 21:605, Abstract 247.1.134. •
   Google Scholar
• LIPPIELLO PM, GRAY JA, PETERS S, GRIGORYAN G, HODGES H, SUMMERS K, GIACOBINI E, COLLINS AC: Metanicotine: a nicotinic agonist with CNS selectivity-in vivo characterization. Neurosci. Abstr. (1995) 21:605, Ab-stract 247.2.
   Google Scholar
• DE FIEBRE CM, MEYER EM, HENRY JC, MURASKIN SI, KEM WR, PAPKE RL: Characterization of a series of anabase-ine-derived compounds reveals that the 3-(4)-dimethy-laminocitutamylidine derivative (DMAC) is a selective agonist at neuronal a7/[5251]-a-bungarotoxin receptor subtypes. Mol. Pharmacol. (1995) 47:164–171.
   PubMed Web of Science ®Google Scholar
• SPANDE TF, GARAFFO HM, EDWARDS MW, YEH HJC, PANNELL L, DALY JW: Epibatidine: a novel (chlo-ropyridybazabicycloheptane with potent analgesic ac-tivity from an Ecuadorian poison frog. J. Am. Chem. Soc. (1992) 114:3475–3478.
   Web of Science ®Google Scholar
• BADIO B, DALY JW: Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. (1994) 45:563–569.
   PubMed Web of Science ®Google Scholar
• QIAN C, LI T, SHEN TY, LIBERTINE-GARAHAN L, ECKMAN J, BIFTU T, IP S: Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol. (1993) 250:R13–R14.
   PubMed Web of Science ®Google Scholar
• SULLIVAN JP, DECKER MW, BRIONI J.D, DONNELLY- ROBERTS D, ANDERSON DJ, BANNON AW, RANG C-H, ADAMS P, PIATTONI-KAPLAN M, BUCKLEY MJ, GOPAIAK-RISHNAN M, WILLIAMS M, ARNERIC SP: (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. (1994) 271:624-631. An important paper to understand some of the safety issues related to the develop of compounds with properties similar to epibatidine, one of the most potent nAChR ligands reported to date.
   Google Scholar
• LIN N-H, HE Y, ARNERIC SP, SULLIVAN JP: Synthesis and structure-activity relationships of 2'-(R) and (S)-pyr-rolidine-modified analogs of the cholinergic channel activator, ABT-418. Blom. Med. Chem. Lett. (1995) 5:1141–1146.
   Web of Science ®Google Scholar
• GARVEY DS, WASICAK JT, ELLIOTT RI, LEBOLD SA, HET-TINGER A-M, CARRERA GM, UN N-H, HE Y, HOLLADAY MW, ANDERSON DJ, CADMAN ED, RASZKIEWICZ JL, SUL-LIVAN JP, ARNERIC SP: Ligands for brain cholinergic channel receptors: synthesis and in vitro charac-terization of novel isoxazoles and isothiazoles as bioi-sosteric replacements for the pyridine ring in nicotine. J. Med. Chem. (1994) 37:4455–4463.
   Google Scholar
• SARASWATI M, LERNER-MARMAROSH N, WANG DX, SHEU S-S, SHARMA V, ABOOD LG: Structure-activity studies of N,N-dialkyl and cycloallcyl carbarnate esters of di-methylethanolarnine and choline with nicotinic and muscarinic cholinergic properties. Drug Dev. Res. (1994) 31:142–146.
   Google Scholar
• LEVIN ED, ROSE JE, ABOOD L: Effects of nicotinic di-methylaminoethyl esters on working memory per-formance of rats in the radial-arm maze. Pharmacol. Biochem. Behav. (1995) 51:369–373.
   PubMed Web of Science ®Google Scholar
• WARD JS, MERRITT L, BYMASTER FP, CALLIGARO DO: Isoarecolones and arecolones: selective central nico-tinic agonists that cross the blood brain barrier. Bioorg Med. Chem. Lett. (1994) 4.573–578.
   Web of Science ®Google Scholar
• REAVILL C, SPIVAK CE, STOLERMAN IP, WATERS JA: Isoarecoline can inhibit nicotine binding and produce nicotine-like discriminative stimulus effects in rats. Neuropharmacology (1987) 26:789–792.
   PubMed Web of Science ®Google Scholar
• DECKER MW, MAJCHRZAK MJ, ARNERIC SP: Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. (1993) 45:571–576.
   PubMed Web of Science ®Google Scholar
• ABOOD LG, SALLES KS, MAM A: Structure-activity stud-ies of carbamate and other esters: agonists and antago-nists to nicotine. Pharmacol. Biochem. Behav. (1988) 30:403–408.
   PubMed Web of Science ®Google Scholar
• DECKER MW, BUCKLE, MJ, BRIONI JD: Differential effects of pretreatment with nicotine and lobeline on nicotine-induced changes in body temperature and loconaotor activity in mice. Drug Dev. Res. (1994) 31:52–58.
   Web of Science ®Google Scholar
• DAILY JW, NISHIZAWA Y, EDWARDS MW, WATERS JA, ARONSTAM RS: Nicotinic receptor-elicited sodium flux In rat pheochromocytoma PC12 cells: effects of agonists, antagonists, and noncompetitive blockers. Neurochem. Res. (1991) 16:489–500.
   PubMed Web of Science ®Google Scholar
• SPIVAK CE, WITKOP B, ALBUQUERQUE EX: Anatoxin-a: a novel potent agonist at the nicotinic receptor. Mol. Pharmacol. (1980) 18:384–394.
   PubMed Web of Science ®Google Scholar
• THOMAS P, STEPHENS MG, AMAR M, LUNT GG, WHITING P, GALLAGHER T, PEREIRA E, ALKONDON M, ALBUQUER-QUE EX, WONNACOTT S: (+)-Anatoxin is a potent agonist at neuronal nicotinic acetylcholine receptors. Neurochem. (1993) 60:2308–2311.
   PubMed Web of Science ®Google Scholar
• SWANSON KL, ARONSTAM RS, WONNACOTT S. RAPOPORT H, ALBUQUERQUE EX: Nicotinic pharmacol-ogy of anatoxin analogs. L Side chain structure-activity relationships at peripheral agonist and noncompetitive antagonist sites. J. Pharmacol. Exp. Ther. (1991) 259:377–386.
   Google Scholar
• THOMAS P, BROUGH PA, GALLAGHER T, WONNACOTT S: Alkyl-modified side chain variants of anatoxhi-a: a series of potent nicotinic agonists. Drug Dev. Res. (1994) 31:147–146.
   Web of Science ®Google Scholar
• WONNACOTT S, JACKMAN S, SWANSON KL, RAPOPORT H, ALBUQUERQUE EX: Nicotinic pharmacology of ana-toxin analogs. II. Side chain structure-activity relation-ships at neuronal nicotinic ligand binding sites. J. Pharmacol, Exp. Ther. (1991) 259:387–391.
   Google Scholar
• SLOAN JW, MARTIN WR, HOOK R, HERNADEZ J: Structure-activity relationships of some pyridine, piperidine and pyrrolidine analogues for enhancing and inhibiting the binding of (±)-[311]-nicotine to the rat brain P2 prepara-tion. J. Med. Chem. (1985) 28:1245–1251.
   PubMed Web of Science ®Google Scholar
• TAYLOR P: Agents acting at the neuromuscular junction and autonomic ganglia. In. Goodman and Gilman 'S The Pharmacological Basis of Therapeutics. Gilman AG, Rail TW, Nies AS, Taylor P (Eds). Pergamon Press, New York (1990):166–186.
   Google Scholar
• JAMES MK: Remifentanil and anaesthesia for the future. Exp. ()pin. Invest. Drugs (1994) 3:331–340.
   Google Scholar
• ARNERIC SP, SULLIVAN JP, BRIGGS CA, DONNELLY-ROBERTS D, ANDERSON DJ, RASZKIEWICZ JL, HUGHES ML, CADMAN ED, ADAMS P, GARVEY DS, WASICAK JT, WILLIAMS M: (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl) Isoxazole (ANT 418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: Lin vitro characterization. J. Pharmacol. Exp. Ther. (1994) 270: 310–318.
   PubMed Web of Science ®Google Scholar
• DECKER MW, BRION' JD, SULLIVAN JP, BUCKLEY MJ, RADEK RJ, RASZKIEWICZ JL, KANG CH, KIM DJB, GIARDINA WJ, WASICAK JT, GARVEY DS, WILLIAMS M, ARNERIC SP: (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl) Isoxazole (ABT 418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp Ther. (1994) 270:319–328.
   PubMed Web of Science ®Google Scholar
• I3RIONI JD, KIM DJB, BRODIE MS, DECKER MW, ARNERIC SP: ABT-418: Discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharrna-cology (1995) 107:368–375.
   Google Scholar
• MEYER EM, DE FIEBRE CM, HUNTER BE, SIMPKINS CE, FRAUWORTH N, DE FIEBRE NEC: Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors . Drug Dev. Res. (1994) 31 :127–134.
   Web of Science ®Google Scholar
• WOODRUFF-PAK DS, LI Y-T, KEM WR: A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. (1994) 645:309–317.
   PubMed Web of Science ®Google Scholar
• WOODRUFF-PAK DS: Evaluation of cognition-enhanc-ing drugs: Utility of the model system of eyeblink classical conditioning. CNS Drug Rev. (1995) 1:107–128.
   Google Scholar
• BRIGGS CA, ANDERSON DJ, BRIONI JD, BUCCAFIJSCO JJ, BUCKLEY MJ, CAMPBELL JE, DECKER MW, DONNELLY-ROBERTS D, IIOLLADAY MW, HUI Y-II, JACKSON WJ, KIM DJB, MARSH KC, O'NEILL A, PRENDEGAST MA, SULLIVAN JP, ARNERIC SP: Functional in vitro and in vivo charac-terization of the novel neuronal acetylcholine receptor ligand GTS-21. Pharmacol. Biochem. Behav. (1995). Sub-mitted.
   Google Scholar
• LLOYD GK, MCDONALD IA, VERNIER J-M, ELLIOTT K, ELLIS 513, SACAAN A, RAO TS, CHAVEZ-NORIEGA L, JOHNSON EC, VELICELEBI /s/NGAGH1 F, HARPOLD M: Subtype-selective cholinergic ion channel agonists as potential antiparkins on agents. The Cholinergic Synapse: Structure, Function and Regulation. Baltimore, MD, November 6–10 (1994) S:45
   Google Scholar
• LLOYD GK, RAO TS, SACAAN A, REID RT, CORREA LD, WHELAN K, RISBROUGH V, MENZAGI II FM: SIB-1765F, a novel nicotinic agonist: profile in models of ex-trapyramidal motor function. Soc. Neurosci. Abstr. (1995) 21:11.10.
   Google Scholar
• RAO TS, SACAAN Al, R_EID R, CORREA L, ADAMS P, BLEICI LER L, COSFORD N, MACDONALD I. LLOYD GK: In vitro characterization of SIB-1765F. Soc. Neurosci. Abstr. (1995) 21:247.4.
   Google Scholar
• LIPPIELLO PM, CALDWELL WS, MARKS MJ, COLLINS AC: Development of nicotinic agonists for Alzheimer's dis-ease treatment. Presented at Tbird International Springfield Symposium on Advances in Alzheimer Therapy. Springfield, IL, May 11-15 (1994):66
   Google Scholar
• SIVILOTTI L, COLQUHOUN D. Acetylcholine receptors: too many channels, too few functions. Science (1995) 269:1681–1682.
   PubMed Web of Science ®Google Scholar